Epilepsia and paroxyzmal conditions

Advanced search


Full Text:


The aim of this study was to investigate the electrophysiological and neurochemical mechanisms of the anticonvulsant effect of a new original compound  GIZH-298 and to define the leading structure as the target for influence compound. Materials and  Methods. The partial (focal) and secondary generalized seizures were modeled by methods of creation a chronic epileptic focus  that was caused  by cobalt applique on the brain of rats. The liquid chromatography  (HPLC) analysis used for neurochemical study of the effect GIZH-298. There was studied the effect on metabolism  and quantity of biogenic amines in the brain structures of rats. Results. It was found that GIZH-298 at a dose of 60 mg / kg (i.p.) has a pronounced effect on the primary and especially secondary generalized epileptic foci in various brain structures with a primary influence on the cortex. GIZH-298 at a dose  of 60 mg / kg caused  a statistically significant increase in the content of serotonin and dopamine in the frontal cortex after 30 minutes after the administration and reduced the rate of metabolism  of dopamine  in the  dorsal striatum.  Conclusion.  The anticonvulsant  effect  GIZH-298  is enhanced  with increased of epileptic system, may be due to increased synthesis of serotonin and dopamine in the cortex, and decreased metabolism  of the latter in the striatum.

About the Authors

S. A. Litvinova
Zakusov Institute of Pharmacology
Russian Federation

Litvinova Svetlana Aleksandrovna – PhD, Psychopharmacology Laboratory Researcher.

Baltiiskaya  ul.,  8,  Moscow,  125315,   Russia.   Tel.:  +7(495)6012414. E-mail:

T. A. Voronina
Zakusov Institute of Pharmacology
Russian Federation

Voronina Tatyana Aleksandrovna – MD, professor,  head of the Laboratory.

Baltiiskaya ul., 8, Moscow, 125315,  Russia.  Tel.: +74956012414.  E-mail:

V. S. Kudrin
Zakusov Institute of Pharmacology
Russian Federation

Kudrin Vladimir Sergeevich – PhD, Head of the Laboratory of Pharmacology neurochemical.

Baltiiskaya  ul.,  8,  Moscow,  125315,   Russia.   Tel.:  +7(495)6012153. e-mail:

I. O. Gaydukov
Zakusov Institute of Pharmacology
Russian Federation

Gaidukov Igor Olegovich – Post-graduate.

125315, Moscow, Baltiiskaya ul., 8. Tel.: +74956012414.  E-mail:

L. N. Nerobkova
Zakusov Institute of Pharmacology
Russian Federation

Nerobkova Lyubov Nikolaevna – PhD., Senior Research Fellow.

Baltiiskaya ul., 8, Moscow, 125315, Russia. E-mail:

M. B. Pisclova
Zakusov Institute of Pharmacology
Russian Federation

G. G. Avakyan
The Russian National Research Medical University named after N. I. Pirogov of the Ministry of Health of the Russian Federation
Russian Federation

Avakyan Georgii Gagikovich – PhD, Department of Neurology, Neurosurgery and Medical Genetics.

Ul. Ostrovityanova, 1, Moscow, 117997, Russia. Tel.: +7(495)5316941.  E-mail:

L. А. Zhmurenko
Zakusov Institute of Pharmacology
Russian Federation

Zhmurenko Lyudmila Aleksandrovna – PhD.

Baltiiskaya ul., 8, Moscow, 125315, Russia


1. Avakyan G. N., Nerobkova L. N., Voronina T. A., Markina N. V., Mitrofanov A. A. Eksperimental’naya i klinicheskaya farmakologiya. 2002; 2: 7-10.

2. Blinov D. V. Epilepsiya i paroksizmal’nye sostoyaniya / Epilepsy and paroxysmal conditions. 2011; 2: 28-33.

3. Buresh Dzh., Petran’ M., Zakhar D. Electrophysiological Methods in Biology [Elektrofiziologicheskie metody issledovaniya v biologii (in Russian)]. Moscow. 1964; 551.

4. Voronina T. A., Nerobkova L. N. Guidelines for the Study of the anticonvulsant activity of pharmacological substances. Guidelines for conducting pre-clinical trials of medicinal products [Metodicheskie ukazaniya po izucheniyu protivosudorozhnoi aktivnosti farmakologicheskikh veshchestv. Rukovodstvo po provedeniyu doklinicheskikh issledovanii lekarstvennykh sredstv (in Russian)]. Moscow. 2012; 1 (14): 235-250.

5. Karlov V. A. Epilepsy in children and adult women and men: a guide for physicians. Guidelines for doctors [Epilepsiya u detei i vzroslykh zhenshchin i muzhchin: rukovodstvo dlya vrachei. Rukovodstvo dlya vrachei (in Russian)]. Moscow. 2010; 720.

6. Lebedeva A. V., Gekht A. B. Nevrologiya, neiropsikhiatriya, psikhosomatika. 2011; 2: 50-56.

7. Pisklova M. V., Litvinova S. A., Narkevich V. B., Kudrin V. S. Study of the effect of topiramate on the content and turnover of monoamines in the brain structures of Wistar rats. Proceedings of the 6th International Conference «Biological basis of individual sensitivity to psychotropic drugs» [Izuchenie vliyaniya topiramata na soderzhanie i oborot monoaminov v strukturakh mozga krys Vistar. Materialy 6-i Mezhdunarodnoi konferentsii «Biologicheskie osnovy individual’noi chuvstvitel’nosti k psikhotropnym sredstvam» (in Russian)]. Moscow. 2015; 78: 50.

8. Porter R. Dzh., Meldrum B. S. Antiepileptics / BG Kattsung. Basic and Clinical Pharmacology [Protivoelepticheskie sredstva / B. G. Kattsung. Bazisnaya i klinicheskaya farmakologiya. Per. s angl. – 2-e izd., pererab. i dop. (in Russian)]. Moscow-Saint Petersburg. 2007; 464-491.

9. Sidorenko K. V., Darenskaya E. Yu. Uspekhi sovremennogo estestvoznaniya. 2014; 6: 128-130.

10. Ahmad S., Fowler L. J. and Whitton P. S. Lamotrigine, carbamazepine and phenytoin differentially alter extracellular levels of 5-hydroxytryptamine, dopamine and amino acids. Epilepsy Res. 2005; 63: 141-149.

11. Bozzi Y., Dunleavy M., Henshall D. Cell signaling underlying epileptic behavior. Front. Behav. Neurosci. 2011; 5: 45.

12. Bozzi Yuri, Emiliana Borrelli. The role of dopamine signaling in epileptogenesis. Front Cell Neurosci. 2013; 7: 157.

13. Bregman F. Le Saux, S. Trottier, P. Chauvel 1, and Y. Maurin. Chronic Cobalt-induced Epilepsy: Noradrenaline Ionophoresis and Adrenoceptor Binding Studies in the Rat Cerebral Cortex. J. Neural Transmission. 1985; 63: 109-118.

14. Clinckers R., Smolders I., Meurs A., Ebinger G. and Michotte Y. Anticonvulsant action of hippocampal dopamine and serotonin is independently mediated by D and 5-HT receptors. J. Neurochem. 2004a; 89: 834-843.

15. Dailey J. W., Yan Q. S., Adams-Curtis L.E., Ryu J. R., Ko K. H., Mishra P. K., Jobe P. C. Neurochemical correlates of anti-epileptic drugs in the genetically epilepsy-prone rat (GEPR). Life Sci. 1996; 58: 259-266.

16. Hauser W. A. Epidemiology of epilepsy. Coll. Mater. X Congress of neurologists Russia with international participation. Nizhny Novgorod 17-21 June 2012 All-Russian Society of Neurologists. 2012; 313-314.

17. Ichikawa J. L., Meltzer H. Y. Valproate and carbamazepine increase prefrontal dopamine release by 5-HT1A receptor activation. Eur J Pharmacol. 1999; 3: 380 (1): R1-3.

18. Muhammad Y. A-Shorbagy, Bahia M. E Sayeh, Dalaal M. Abdallah. Additional Antiepileptic Mechanisms of Levetiracetam in Lithium-Pilocarpine Treated Rats. 2013; URL: http:// PLOS Medicine, dx.doi. org/10.1371/journal.pone.0076735. Accessed: 06.04.2016.

19. Okada M., Kaneko S., Hirano T., Ishida M., Kondo T., Otani K. and Fukushima Y. Effects of zonisamide on extracellular levels of monoamine and its metabolite, and on Ca2+dependent dopamine release. Epilepsy Res. 1992; 13: 113-119.

20. Parada A., Soares-da-Silva P. The novel anticonvulsant BIA 2-093 inhibits transmitter release during opening of voltage-gated sodium channels: a comparison with carbamazepine and oxcarbazepine. Neurochem Int. 2002; 40 (5): 435-40.

21. Pasini A., Tortorella A., Gale K. Anticonvulsant effect of intranigral fluoxetine. Brain Res. 1992; 287-290.

22. Prendiville S., Gale K. Anticonvulsant effect of systemic fluoxetine on focally-evoked limbic motor seizures in rats. Epilepsia. 1993; 34: 381-384.

23. Samuel D., Blin O., Dusticier N., Nieoullon A. Effects of riluzole (2-amino-6trifluoromethoxy benzothiazole) on striatal neurochemical markers in the rat, with special reference to the dopamine, choline, GABA and glutamate synaptosomal high affinity uptake systems. Fundam Clin Pharmacol. 1992; 6 (4-5): 177-84.

For citation:

Litvinova S.A., Voronina T.A., Kudrin V.S., Gaydukov I.O., Nerobkova L.N., Pisclova M.B., Avakyan G.G., Zhmurenko L.А. ELECTROPHYSIOLOGICAL AND NEUROCHEMICAL STUDIES OF THE MECHANISMS OF THE ANTICONVULSANT EFFECT OF THE NEW ORIGINAL COMPOUND GIZH-298. Epilepsia and paroxyzmal conditions. 2016;8(3):19-26. (In Russ.)

Views: 226

ISSN 2077-8333 (Print)
ISSN 2311-4088 (Online)